Ruben Olivares, MD

Olivares cautioned that HIFU is not suitable for all patients, particularly those with more aggressive disease, for whom complete gland removal may still be necessary.

A primary concern was establishing trust in the connectivity to ensure no loss in visualization or connection.

The panel offers key takeaways on the evolving landscape for imaging and biopsy in prostate cancer, highlighting the role for fusion-guided biopsy in the diagnosis and management of prostate cancer.

Prostate cancer specialists provide insights on the integration of fusion biopsy into clinical practice and how it has impacted treatment paradigms.

The panel discusses how fusion-guided biopsy can inform patient eligibility for focal therapy in prostate cancer.

A panel of experts on prostate cancer discuss the role for fusion-guided biopsies in active surveillance for patients with prostate cancer.

Focusing on the role of systematic biopsy, the panel provides clinical insights on biopsy practice patterns after encountering suspicious-looking areas on MRI.

Experts on prostate cancer focus on the differences between fusion-guided technologies, highlighting cognitive-based and software-based fusions.

The panel discusses data on the accuracy of MRI-targeted or fusion-based biopsy procedures compared with systemic biopsy or MRI alone.

Firas F. Abdollah, MD, provides insights on how MRI- or fusion-guided technologies are used with transrectal and transperineal biopsy procedures and how they improve traditional biopsy procedures.

Focusing on prostate cancer diagnosis, the panel discusses transrectal and transperineal biopsies and limitations associated with them.

A panel of experts on prostate cancer introduce themselves and begin the discussion with clinical insights on diagnostic practices and the importance of biopsy and imaging in guiding treatment decisions.